BioCardia Reports Narrower Losses Across Both Reporting Windows in Interim Filing

Bottom line

The bottom line for BioCardia, Inc. over both windows presented in this interim filing is the same on a direction basis: a loss rather than a profit. Net Income (Loss) Attributable to Parent sits in negative territory for the three-month reporting period, the prior-year comparative three-month period, the six-month year-to-date period, and the prior-year comparative six-month period; the same is true of Operating Income (Loss) across all four windows. Year over year, the authorized relation is an improving one on both metrics — the loss narrows on the three-month window, and it also narrows on the six-month window — but the filing remains in loss-to-loss territory in every case. No top-line revenue figure, cash-balance figure, or per-share figure is available in the filing evidence for this section, so profitability is described here only by direction.

The reporting identity is fixed by the filing itself: it is a 10-Q filed by BioCardia, Inc. under accession 0001437749-26-027315 with CIK 0000925741 and ticker BCDA, covering fiscal period period-ended-2026-06-30. The two reportable income-statement windows the filing presents are the three-month reporting period and the prior-year comparative three-month period, plus the six-month year-to-date period and the prior-year comparative six-month period.

Management frames the company as a clinical-stage developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary indications, with substantially all resources so far devoted to research and development, and operations funded primarily through equity, convertible debt, and grants. Management also flags forward-looking-statement risk and notes that interim condensed consolidated financial statements for the three- and six-month windows have been prepared in accordance with U.S. GAAP on a basis consistent with prior annual statements, with only normal recurring adjustments. Management explains that interim results are not necessarily indicative of full-year or other future outcomes.

Because management has not disclosed which line item, cost category, or one-time item drove the period-over-period movement, no inference about the source of the narrowing loss is offered. The filing evidence does not attribute this change to any single cause.

None presented in this section. The filing evidence does not pair the reported direction with a contrary quantitative disclosure, and management does not describe any offsetting weakness or distinguishing event.

UNKNOWN: The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison.

Financial performance

- For the three-month period, BioCardia, Inc. (BCDA) reported Net Income (Loss) Attributable to Parent of -$1,613,000 in the three months ended June 30, 2026, a loss, versus -$2,049,000 in the three months ended June 30, 2025, also a loss; on a year-over-year basis the loss narrowed, an authorized loss-to-loss improvement. - For the six-month year-to-date window, Net Income (Loss) Attributable to Parent was -$3,872,000 in the six months ended June 30, 2026, compared with -$4,761,000 in the six months ended June 30, 2025, again a loss in both periods; the authorized direction is an increase (a smaller loss) against the prior year, with the same loss-to-loss transition.

- Operating Income (Loss) tracked the same pattern: -$1,623,000 for the three months ended June 30, 2026 versus -$2,051,000 for the three months ended June 30, 2025, both losses, and the authorized transition is loss to loss with a narrower year-over-year loss. - For the half year, Operating Income (Loss) was -$3,889,000 in the six months ended June 30, 2026 against -$4,777,000 in the six months ended June 30, 2025, also losses in both periods, again narrowing year-over-year on an authorized loss-to-loss basis. - On a quarter-over-quarter lens, both reported figures remain losses rather than profits, so the comparison is best framed as a continued-loss trajectory with the most recent three-month loss position sitting against the prior-year quarter; the catalog does not authorize a separate quarter-versus-quarter movement statement for these lines.

- Management frames BioCardia, Inc. as a clinical-stage therapeutic delivery platform that has devoted substantially all of its resources to research and development, has generated only modest revenues from approved products, and funds operations primarily through equity and convertible debt sales plus certain grants. The MD&A in this 10-Q for period-ended-2026-06-30 (accession 0001437749-26-027315) emphasizes that operating losses and negative cash flows are expected to continue for the next several years as trials and development activities expand.

- Management explicitly raises substantial doubt about the entity's ability to continue as a going concern beyond roughly January of the following year without additional funding, citing cash and cash equivalents of approximately the disclosed amount as of the balance-sheet date. Relief is described as contingent on plans to raise capital through non-dilutive collaborations and licensing, debt, equity, or a combination, which management believes will alleviate the doubt but which are not entirely within its control and cannot yet be assessed as probable of occurring.

S. GAAP on a basis consistent with the annual statements, with only normal recurring adjustments. Certain prior period balances have been reclassified to conform to the current presentation, a routine accounting context item to flag when reading the comparatives.

Significant items subject to estimate include clinical accruals, share-based compensation, and right-of-use assets and related liabilities, including the assumed incremental borrowing rate. - Operations are managed as a single segment reviewed by the president and chief executive officer, so the comparative baselines above are not segmented further in this filing. The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison, and management did not provide forward numerical guidance, so any wider benchmarking or projection must rely on filings outside this 10-Q. The filing evidence contains no peer or industry comparison.

Operating drivers and segments

- The filing states that BioCardia, Inc. manages its operations as a single reporting segment, with the chief operating decision maker (the president and chief executive officer) reviewing financial performance and allocating resources at that consolidated level. - No segment revenue, segment operating loss, or segment margin breakdown is presented; segment-level evidence is therefore not a separate input here.

- The operating result for the three-month reporting period was -$1,623,000, compared with -$2,051,000 for the prior-year comparative — both losses, with the current period a smaller loss than the prior period on a quarter basis. - The operating result for the six-month year-to-date period was -$3,889,000, compared with -$4,777,000 — again both losses, with the current six-month loss smaller than the prior-year six-month loss. - Counter-evidence on segments: the cited note and the summary-of-business language confirm a one-segment view; there is no second segment, geographic split, or product-line split disclosed that could independently verify the consolidated operating loss.

- Management describes BioCardia, Inc. as a clinical-stage company whose activities center on the CardiAMP and CardiALLO cell therapy programs, the PulmALLO program, and the Helix and Morph delivery platforms, with partnering of the delivery platform to other biotherapeutic developers. - Management states that, to date, substantially all resources have been devoted to research and development, including clinical trials, manufacturing and sales capability-building, in-licensing, and general and administrative support, with only modest revenues from approved-product sales.

- Management frames the cost base as having been funded primarily through equity and convertible debt securities and certain government and private grants, rather than from product revenue. - Management does not, in the quoted evidence, attribute the year-over-year narrowing of the operating loss on either the quarter or the six-month window to any single driver; no line-item bridge between the current and prior-period operating losses is provided in the quoted text. - The cautionary forward-looking statement language highlights capital-raising needs, advancement of product candidates, and execution of corporate strategy as the recurring themes, without quantifying their contribution to the current period's loss.

- Independent analysis can confirm only that the operating loss narrowed on both windows versus the prior-year comparatives, in line with the authorized direction of increase (a smaller loss). The filing evidence does not attribute this change to any single cause. - Independent analysis can confirm only that the operating loss narrowed on both windows versus the prior-year comparatives, in line with the authorized direction of increase (a smaller loss).

The filing evidence does not attribute this change to any single cause.

Cash flow and capital

BioCardia, Inc.'s period-ended-2026-06-30 10-Q under accession 0001437749-26-027315 (ticker BCDA, CIK 0000925741) presents a balance sheet dated the balance sheet date of June 30, 2026 and a six-month year-to-date cash flow statement that together frame how the company is being financed while it remains in a loss position.

Reported facts - Operating cash use widened year over year on the six-month view. Net Cash Provided by (Used in) Operating Activities was -$3,394,000 USD for the six months ended June 30, 2026, compared with -$3,267,000 USD for the six months ended June 30, 2025. Both comparative periods are negative, and the authorized direction is a decrease. - Net Cash Provided by (Used in) Investing Activities was -$3,000 USD for the six months ended June 30, 2026 and -$1,000 USD for the six months ended June 30, 2025; both are negative, and the authorized direction is a decrease. - Net Cash Provided by (Used in) Financing Activities was $5,018,000 USD for the six months ended June 30, 2026, against $1,877,000 USD for the six months ended June 30, 2025; both are positive, and the authorized direction is an increase. - Capital spending rose. Payments to Acquire Property, Plant, and Equipment were $3,000 USD for the six months ended June 30, 2026 versus $1,000 USD for the six months ended June 30, 2025, with both periods positive and an authorized direction of increase. - On the balance sheet at the balance sheet date of June 30, 2026, Cash and Cash Equivalents, at Carrying Value stood at $4,117,000 USD, Accounts Payable, Current at $541,000 USD, and Accounts Receivable, after Allowance for Credit Loss, Current at $30,000 USD.

Management explanations - The filing discloses an at-the-market Sales Agreement with HCW as sales agent, under which the company may offer and sell common stock from time to time and pay a commission equal to a stated percentage of gross proceeds. The previously filed Registration Statement on Form noted in the narrative is referenced as the shelf enabling those sales. - The operating lease for the laboratory and corporate offices is described as carrying a stated weighted average remaining lease term and weighted average discount rate at the period end, with an extension option that is conditional on the company not being in default and remaining in occupancy. - A general fair value hierarchy is restated, defining Level 1, Level 2 and Level 3 inputs used in valuing financial instruments.

Analyst inference - The combination of higher financing inflows and higher operating cash outflow over the six-month window, with investing outflows also lower, is consistent with the company funding its clinical-stage operating gap with external capital while still deploying modest amounts into property, plant, and equipment. - The relative size of cash and cash equivalents against the working-capital line items on the the balance sheet date of June 30, 2026 balance sheet is the key liquidity indicator visible in this section.

Counter-evidence and unknowns - The narrative does not quantify how much of the financing inflow came from the ATM program versus other sources, so the contribution of the Sales Agreement to the year-over-year financing change is not disclosed. The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The specific causes of the wider operating cash use and the larger investing outflow are not itemized in the quoted material. The filing evidence does not attribute this change to any single cause. - For researchers who also follow other clinical-stage filings, the parallel six-month progression discussed in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing is offered only as a contrasting reference point, not a like-for-like benchmark.

Peer and historical context

- BioCardia's reported net loss for the three-month period narrowed compared with the prior-year quarter, based on the reported comparison for BioCardia, Inc.'s 10-Q filed under 0001437749-26-027315 for period-ended-2026-06-30. The figure moved in the favorable direction (a smaller loss rather than a larger one), though it remained a loss against the prior-year loss rather than crossing into profit. - The net loss for the six-month year-to-date period likewise narrowed relative to the prior-year comparative on the same authorized basis, again moving from a loss to a smaller loss. The directional improvement is consistent across both reporting windows. - Operating loss for the three-month window contracted against the prior-year quarter, and operating loss for the six-month window contracted against the prior-year comparative. Both moves are favorable on the authorized scale, yet profitability was not achieved in either period. - Operating cash outflow for the six-month year-to-date period decreased relative to the prior-year comparative, indicating a softer cash burn alongside the narrower operating loss. This is one of the few dimensions in the catalog where the year-over-year direction is a decrease rather than a narrowing loss, and it tracks loosely with the operating-loss improvement on the same six-month basis. - Across all four loss and cash-flow dimensions, the picture is one of contraction rather than expansion: smaller losses and a smaller cash outflow, but no return to positive territory on any line item the catalog supports.

- The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute this change to any single cause. - Reading the four loss dimensions in isolation could suggest a clean improvement story, but each is still a loss, and the catalog does not contain any revenue, gross profit, or operating-expense breakout that would let a reader reconcile the narrower operating loss against underlying top-line activity. - The narrower operating cash outflow for the six-month window is consistent with the narrower operating loss, but the catalog provides no line-item detail on working-capital movements, deferred items, or non-cash add-backs, so the relationship between accrual loss and cash burn cannot be verified beyond direction. - Several contextual items in the source narrative are relevant to a multi-period view but do not produce quantitative anchors: the operating lease expiration language, the at-the-market Sales Agreement and commission disclosure, and the income-tax footnote describing a full valuation allowance on deferred tax assets. Each of these would typically shape a peer or historical read-through, yet the catalog contains no comparable figure across periods to weigh them against.

- No segment-level detail is disclosed for any of the dimensions above, so any cross-business comparison is unavailable. - BioCardia's common stock equivalents — options, warrants, and restricted stock units — were excluded from diluted loss per share as antidilutive, which means historical per-share figures cannot be re-cast on a diluted basis for a cleaner cross-period comparison. - The going-concern and contingent-proceedings disclosures in the source narrative are qualitative only; the catalog contains no liquidity, runway, or reserve figure against which to benchmark current versus prior-period standing.

Readers comparing this filing against the company's own historical windows should rely on the directional narrowing described above and resist any inference about margin trajectory, since the catalog does not disclose the underlying revenue or cost components that would anchor such a read.

Scenario analysis

In the base case, BioCardia, Inc. continues its current trajectory as a clinical-stage developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Net Income (Loss) Attributable to Parent remains a loss on both reporting windows for the period filed on 10-Q under accession 0001437749-26-027315, matching the prior-year comparative position. The six-month year-to-date net loss for the six months ended June 30, 2026 is reported as -$3,872,000 USD, narrower than the prior-year comparative of -$4,761,000 USD for the six months ended June 30, 2025, consistent with the authorized year-over-year direction. The three-month net loss for the three months ended June 30, 2026 is reported as -$1,613,000 USD, narrower than the prior-year comparative of -$2,049,000 USD for the three months ended June 30, 2025. The filing evidence does not attribute this change to any single cause. The company retains an at-the-market facility through HCW and a prospectus supplement allowing intermittent share issuances, providing a financing bridge while clinical programs advance.

In the more constructive case, continued quarter-over-quarter narrowing of the net loss signals improving operating efficiency on both reporting windows relative to the prior year. Year-to-date net loss at -$3,872,000 USD improves versus the prior-year comparative at -$4,761,000 USD for the six months ended June 30, 2025, and the quarterly net loss at -$1,613,000 USD improves against -$2,049,000 USD for the three months ended June 30, 2025. The filing evidence does not attribute this change to any single cause. Cash usage from operating activities trends in line with the authorized year-over-year direction disclosed for the period filed under period-ended-2026-06-30 by 0000925741, while the financing-activity line moves in its authorized direction. No income tax expense or benefit is recognized for federal or state purposes during either window because a full valuation allowance offsets deferred tax assets, leaving future taxable income as the swing variable. The deferred tax realization question stays unresolved until sustained profitability emerges.

In the more adverse case, the loss persists at or above the prior-year comparative levels rather than narrowing. The six-month net loss of -$3,872,000 USD for the six months ended June 30, 2026 and the quarterly net loss of -$1,613,000 USD for the three months ended June 30, 2026 fail to improve against the prior-year comparatives of -$4,761,000 USD and -$2,049,000 USD, respectively. The filing evidence does not attribute this change to any single cause. Cash consumed by operating activities expands more rapidly than the authorized direction permits, while property, plant, and equipment additions for the six months ended June 30, 2026 rise versus the six months ended June 30, 2025, absorbing additional liquidity. The ATM facility remains the principal financing channel, and any restriction on share issuances under the Sales Agreement or related Registration Statement could compress the runway. Antidilutive securities — stock options, warrants, and restricted stock units excluded from diluted share counts — become more relevant if equity raises are required at unfavorable prices. Risks and contingencies discussed under Item 1A frame the surrounding uncertainty, though The filing evidence contains no peer or industry comparison. and The filing evidence does not disclose segment-level detail for this dimension. apply for benchmarking the loss trajectory.

Risks and what to watch

- The filing repeats a warning that forward-looking commentary could differ materially from actual outcomes because of the risk factors described in the Form 10-Q for BioCardia, Inc. (BCDA) under accession 0001437749-26-027315. That umbrella risk is the most relevant frame for what follows: small-cap clinical-stage names can swing sharply on news that has nothing to do with the income statement.

- Reported fact — the three-month period the three months ended June 30, 2026 delivered a net loss attributable to parent of -$1,613,000, narrower than the prior-year comparative for the three months ended June 30, 2025 at -$2,049,000, and the six-month year-to-date period the six months ended June 30, 2026 also produced a loss attributable to parent of -$3,872,000, narrower than the prior-year comparative for the six months ended June 30, 2025 at -$4,761,000. The direction on both windows is improvement, but the transition on both is loss to loss, so the change is in magnitude, not in profitability.

- Management explanation — the filing attributes the absence of an income tax benefit to the net loss position together with a full valuation allowance against deferred tax assets, and it states that realization of those deferred tax assets depends primarily on future taxable income that is not certain. Diluted shares equal basic shares across every period presented because common stock equivalents — stock options, warrants, and restricted stock units — are antidilutive in a loss period. Management also notes it is not aware of any current legal or administrative proceedings likely to have an adverse effect on the business.

- Analyst inference — the antidilutive overhang from unvested restricted stock units, warrants, and options means that any future swing into profit would mechanically expand the diluted share count and reduce per-share metrics relative to the basic view. The deferred-tax full valuation allowance is also worth flagging: it caps any near-term tax shield value, so even a one-time pre-tax gain would likely translate close to dollar-for-dollar to the bottom line. - Counter-evidence and unknowns — there is no segment-level disclosure for revenue, operating expense, or operating loss in the filing evidence, and there is no peer or industry comparison in this filing; both are absent rather than misstated, so cross-sectional context is not available here.

The filing also does not break out share counts, expense composition, or fair-value hierarchy detail beyond the citations, so the reader cannot independently weigh the components of the operating loss. - The filing evidence does not attribute this change to any single cause. - Metrics to watch next period — track whether the loss attributable to parent continues to narrow on both the three-month and six-month windows, whether cash used in operating activities continues to compress in line with the six-month trend already authorized, and whether any future swing to profitability coincides with disclosure of a larger diluted share count from the antidilutive overhang currently excluded from the denominator.

Readers modeling clinical-stage burn rates for BioCardia, Inc. may also want to compare this interim pattern with the same windows at peers covered elsewhere on Lizely Finance, such as the period-ended interim work on REINSURANCE GROUP OF AMERICA INC for a profit-side comparator.